MARKET

ASMB

ASMB

Assembly Bioscie
NASDAQ
1.650
-0.010
-0.60%
After Hours: 1.630 -0.02 -1.21% 16:13 02/07 EST
OPEN
1.700
PREV CLOSE
1.660
HIGH
1.700
LOW
1.630
VOLUME
132.46K
TURNOVER
--
52 WEEK HIGH
2.420
52 WEEK LOW
0.8200
MARKET CAP
80.49M
P/E (TTM)
-0.5883
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB) and Evolus (EOLS)
TipRanks · 01/30 09:20
H.C. Wainwright Keeps Their Hold Rating on Assembly Biosciences (ASMB)
Tip Ranks · 12/29/2022 11:25
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs
Benzinga · 12/19/2022 20:19
Assembly Biosciences Announces Interim Results From Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 And ABI-4334
Benzinga · 12/19/2022 13:10
BRIEF-Assembly Biosciences Announces Promising Interim Results From Two Clinical Trials Evaluating Next-Generation Core Inhibitor Candidates
Reuters · 12/19/2022 13:06
Assembly Biosciences Reports 'Promising' Interim Results of Early Trials in Hepatitis B; Shares Rise
Assembly Biosciences Reports 'Promising' Interim Results of Early Trials in Hepatitis B; Shares Rise
MT Newswires · 12/19/2022 11:24
Mizuho Maintains Buy on Assembly Biosciences, Lowers Price Target to $3
Benzinga · 11/16/2022 13:29
--Mizuho Cuts Price Target on Assembly Biosciences to $3 From $14, Keeps Buy Rating
--Mizuho Cuts Price Target on Assembly Biosciences to $3 From $14, Keeps Buy Rating
MT Newswires · 11/15/2022 09:43
More
About ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of therapeutics targeting hepatitis B virus (HBV) and other viral diseases. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H3733, and ABI-4334. Vebicorvir (VBR) is its lead core inhibitor product candidate, which is licensed from Indiana University. VBR is developed for the treatment of the treatment of patients with chronic HBV infection. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company is conducting Phase I study of 3733. The Company’s research and development programs pursue multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.

Webull offers kinds of Assembly Biosciences Inc stock information, including NASDAQ:ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASMB stock methods without spending real money on the virtual paper trading platform.